Headlines about healthcare companies from public financial news over the last 30 days, scored for sentiment and importance.
Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Intuitive Surgical's $450 million settlement weighs on Q3 earnings, but strong revenues and procedure growth highlight underlying momentum.
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
The health insurer's turnaround is lifting earnings. Here's what annual growth between 13% and 16% could mean for its stock by 2029.
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy.
This surprising healthcare stock has been outperforming the markets this year.
The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.
Key TakeawaysEli Lilly closed Friday worth $1. 27 trillion, about 10% short of Tesla’s value, after a week when Tesla and the AI trade sold off.
We just published a list of the 10 Best All-Time High Stocks to Buy According to Wall Street and Labcorp (NYSE:LH) ranked 10th on this list. Wall Street’s leadership changed hands over the past month. The technology and chip stocks that…
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Novo got a much-needed boost from its latest earnings report.
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
The Dow Jones index falls Friday after a strong October jobs report. Nvidia stock gains after an AI trade rout.
Moby summary of Humana Inc.'s Q3 2026 earnings call
Moby summary of Moderna, Inc.'s Q3 2026 earnings call
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
The company lifted its sales outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue.
The separation of CVS Health could present an opportunity for its retail pharmacies. Meanwhile, higher costs are impacting the luxury apparel brand.
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
These are some of the stocks posting the largest moves premarket.
After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's, while others spotted fresh…
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Natera, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenues for the quarter reached $794.0 million, representing an increase of 34.1% compared to $592.2 million in the third quarter of…
Revolution Medicines’ brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Danaher Corp (Symbol: DHR) has taken over the #44 spot from Abbott Laboratories (Symbol: ABT), according to ETF Channel. Below…
Gilead Sciences increased its quarterly dividend by 3.8% this year.
The Wegovy maker raised its outlook again and the stock jumped. But its CEO refused to forecast next year, and handed investors six clues instead.
The healthcare giant surprised analysts with the decision to separate its business. Its stock fell.
The move would reverse the company's $78 billion acquisition of Aetna and dismantle the vertically integrated healthcare conglomerate it created in 2018.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own.
Here are some of the companies making headlines in midday trading.
SpaceX and Tesla fall as Democrats win control of Congress.
CVS Health Corporation announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The…
These are the stocks posting the largest moves in the premarket.
Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that has been launched this year.
Pfizer Inc. announced that its Board of Directors unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026. Ms. Guegan, 55, was previously appointed as…
Gov. Greg Abbott is facing a surprisingly strong challenge that could have significant policy implications.